NanoViricides Inc (NYSE MKT:NNVC) — Market Cap & Net Worth
Market Cap & Net Worth: NanoViricides Inc (NNVC)
NanoViricides Inc (NYSE MKT:NNVC) has a market capitalization of $21.57 Million ($21.57 Million) as of May 22, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #24897 globally and #5167 in its home market, demonstrating a -9.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NanoViricides Inc's stock price $1.55 by its total outstanding shares 21568429 (21.57 Million). Analyse NNVC cash generation efficiency to see how efficiently the company converts income to cash.
NanoViricides Inc Market Cap History: 2015 to 2026
NanoViricides Inc's market capitalization history from 2015 to 2026. Data shows change from $509.01 Million to $33.43 Million (-23.48% CAGR).
NanoViricides Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NanoViricides Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NNVC by Market Capitalization
Companies near NanoViricides Inc in the global market cap rankings as of May 22, 2026.
Key companies related to NanoViricides Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
NanoViricides Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, NanoViricides Inc's market cap moved from $509.01 Million to $ 33.43 Million, with a yearly change of -23.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $33.43 Million | +37.17% |
| 2025 | $24.37 Million | -20.98% |
| 2024 | $30.84 Million | +40.20% |
| 2023 | $22.00 Million | -8.11% |
| 2022 | $23.94 Million | -70.16% |
| 2021 | $80.23 Million | +29.62% |
| 2020 | $61.90 Million | +14.34% |
| 2019 | $54.14 Million | -37.25% |
| 2018 | $86.27 Million | -77.28% |
| 2017 | $379.65 Million | -17.75% |
| 2016 | $461.56 Million | -9.32% |
| 2015 | $509.01 Million | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of NanoViricides Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.57 Million USD |
| MoneyControl | $21.57 Million USD |
| MarketWatch | $21.57 Million USD |
| marketcap.company | $21.57 Million USD |
| Reuters | $21.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more